MedTrace Logo

Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.

NCT02456506 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2020-03-24

No results posted yet for this study

Summary

This study evaluates the hyperfractionated IMRT in the treatment of patients with locally recurrent nasopharyngeal carcinoma. Half of participants will receive hyperfractionated IMRT, while the other half will receive conventional fraction IMRT.

Conditions

  • Nasopharyngeal Neoplasms
  • Mortality
  • Quality of Life
  • Complications

Interventions

RADIATION

Hyperfractionated IMRT

RADIATION

Conventional Fraction IMRT

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Ming-Yuan Chen, MD, PhD · Sun Yat-sen University

  • Yi Pan, MD, PhD · Guangdong Provincial People's Hospital

  • Dong-Ping Chen, MD, PhD · Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456506 on ClinicalTrials.gov